Walid Chriaa, CEO of SIPHAT, explains the history of the public company’s position in Tunisia, as the pearl of the Tunisian pharmaceutical industry. He also points out a few of the strategies in place to counter the financial struggles that SIPHAT has been under, such as reforms with a 2030 vision and a focus on new therapeutic lines.
Mr. Chriaa, what is SIPHAT exactly and how have you begun your first 65 days in office?
"SIPHAT will remain true to its main purpose, being a support institution to the state in its healthcare policies."
